- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00998751
Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)
December 8, 2018 updated by: AB Science
Phase 2 Study of Oral AB1010 in Non Pre-treated, Inoperable Patients With Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)
The objective is to evaluate the efficacy and safety of AB1010 at 7.5 mg/kg/day in the treatment of non pre-treated, inoperable patients with locally advanced/metastatic GIST.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Villejuif, France
- Lecesne
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or Female patients, age >18
- Life expectancy > 6 months
- Histological proven, metastatic, or locally advanced and non-operable, non- pre-treated GIST.
- Patients having never received any tyrosine kinase inhibitor, including as adjuvant therapy
- C-Kit (CD117) positive tumors detected immuno-histochemically
- Measurable tumor lesions with longest diameter >20 mm using conventional techniques or >10 mm with spiral CT scan
Exclusion Criteria:
- Documented allergy to the similar drug of AB1010
- Inadequate organ function
- Patients with a history of any other malignancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: masitinib (AB1010)
oral masitinib 7.5 mg/kg/day
|
7.5 mg/kg/day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Objective response rate according to Response Evaluation Criteria In Solid Tumors (RECIST)
Time Frame: 2 months
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression Free Survival
Time Frame: until disease progression
|
until disease progression
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2005
Primary Completion (Actual)
June 1, 2013
Study Completion (Actual)
June 1, 2013
Study Registration Dates
First Submitted
October 19, 2009
First Submitted That Met QC Criteria
October 19, 2009
First Posted (Estimate)
October 20, 2009
Study Record Updates
Last Update Posted (Actual)
December 11, 2018
Last Update Submitted That Met QC Criteria
December 8, 2018
Last Verified
December 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AB04016
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastro-intestinal Stromal Tumours
-
Centre Leon BerardRecruiting
-
AB ScienceCompletedGastro Intestinal Stromal TumorFrance
-
Institut BergoniéFrench Sarcoma GroupRecruitingGastro Intestinal Stromal TumorFrance
-
University Medical Center GroningenDutch Cancer SocietyRecruitingGastro-intestinal Stromal TumorNetherlands
-
Centre Leon BerardGustave Roussy, Cancer Campus, Grand ParisCompletedSarcoma | Gastro-intestinal Stromal Tumors (GIST)France
-
National University Hospital, SingaporeUnknownAsian Patients With Advanced Gastro-intestinal Stromal Tumors (GIST) Treated With ImatinibSingapore
-
AB ScienceTerminatedGastro-Intestinal Stromal Tumour
-
University Medical Center GroningenDutch Cancer SocietyRecruiting
-
AB ScienceTerminatedGastrointestinal Stromal TumorsUnited States, France, Lebanon
-
Maastricht University Medical CenterCatharina Ziekenhuis EindhovenCompleted
Clinical Trials on oral masitinib
-
AB ScienceCompletedMultiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Relapse FreePoland, Spain, Bulgaria, France, Germany, Greece, Romania
-
AB ScienceCompletedAsthmaSpain, Bulgaria, Czechia, France, Hungary, India
-
AB ScienceRecruitingProgressive Multiple SclerosisSpain, Sweden, France, Greece, Italy, Poland, Russian Federation, Ukraine
-
AB ScienceCompletedAsthmaMalaysia, Argentina, Peru, Philippines, Ukraine
-
AB ScienceCompleted
-
AB ScienceCompleted
-
AB ScienceRecruitingCovid19 | Coronavirus Disease 2019 | SARS-CoV2 InfectionFrance, Russian Federation, South Africa
-
AB ScienceRecruitingMast Cell Activation SyndromeFrance, United States
-
AB ScienceTerminatedGastro-Intestinal Stromal Tumour
-
AB ScienceCompleted